Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 582,131 | 407,173 | 260,852 | 111,856 | 427,792 |
| Depreciation Amortization | 95,998 | 71,437 | 46,786 | 23,204 | 88,011 |
| Income taxes - deferred | -38,082 | -3,363 | 2,658 | 2,853 | 6,162 |
| Accounts receivable | -60,722 | -72,409 | -57,277 | -38,062 | -22,472 |
| Accounts payable and accrued liabilities | 981 | 512 | -6,729 | -1,755 | 1,957 |
| Other Working Capital | -31,761 | -76,842 | -95,415 | -121,542 | -104,969 |
| Other Operating Activity | 99,518 | 102,621 | 85,138 | 51,317 | 62,677 |
| Operating Cash Flow | $648,063 | $429,129 | $236,013 | $27,871 | $459,158 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -250 | N/A | N/A | N/A | N/A |
| PPE Investments | -106,958 | -92,768 | -73,558 | -49,002 | -154,969 |
| Net Acquisitions | -1,500 | N/A | N/A | N/A | -50,304 |
| Purchase Sale Intangibles | -668 | -918 | -668 | -668 | -255 |
| Other Investing Activity | -668 | -918 | -668 | -668 | -255 |
| Investing Cash Flow | $-109,376 | $-93,686 | $-74,226 | $-49,670 | $-205,528 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -289,625 | -289,625 | N/A | 198,110 | -110,275 |
| Debt Issued | 200,000 | 200,000 | 200,000 | N/A | 100,000 |
| Common Stock Issued | 51,328 | 39,230 | 20,613 | 10,210 | 36,106 |
| Common Stock Repurchased | -203,418 | -191,844 | -191,483 | -191,419 | -309,711 |
| Other Financing Activity | -6,701 | -6,575 | -173,760 | 0 | -2,529 |
| Financing Cash Flow | $-248,416 | $-248,814 | $-144,630 | $16,901 | $-286,409 |
| Exchange Rate Effect | 3,331 | -1,368 | -2,190 | -4,033 | -689 |
| Beginning Cash Position | 90,326 | 90,326 | 90,326 | 90,326 | 123,794 |
| End Cash Position | 383,928 | 175,587 | 105,293 | 81,395 | 90,326 |
| Net Cash Flow | $293,602 | $85,261 | $14,967 | $-8,931 | $-33,468 |
| Free Cash Flow | |||||
| Operating Cash Flow | 648,063 | 429,129 | 236,013 | 27,871 | 459,158 |
| Capital Expenditure | -106,958 | -92,768 | -73,558 | -49,002 | -154,969 |
| Free Cash Flow | 541,105 | 336,361 | 162,455 | -21,131 | 304,189 |